Dr. Reddy’s Labs (RDY) Announces Settlement Agreement Related to Lipitor with Pfizer (PFE)
Tweet
Share
E-mailGet Alerts RDY Hot Sheet
Up)Join SI Premium – FREE
Dr. Reddy’s Laboratories (NYSE: RDY) has entered into a settlement agreement with Pfizer (NYSE: PFE) which will resolve litigation related to Lipitor® Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, known generically as Atorvastatin Calcium tablets. The terms of the agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
- Tactile Systems Technology (TCMD) Announces CEO Transition and Preliminary First Quarter 2024 Revenue
- Waterstone Financial (WSBF) Expands Share Buyback by 2M
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
